On the last CC company mentioned that Pfizer would be making some decisions re continuing collaboration in September. Could the recent strength be someone frontrunning the news in expectation of a positive outcome? Hard to find any objective explanation, but it's been a pretty impressive few days, at least from a relative strength perpective. Cant't really be excited under $5.80, though. Still optimistic, but not patient.
There's no mojo in this market or this stock. There are no near term catalysts that we know of to make the stock move higher at this time. The underlying story is intact, however, and the prospects for this company appear very good, IMO. It's a good time to buy if you can accept some risk. The naysayers are now just as prevalent as the cheerleaders were before. Means nothing.
It wasn't actually a boatload. But that's all relative to ones resources, isn't it? Only a fraction of the shares I sold. And it was a little bit higher than 16.30. My best price is 16.74, several purchases in the $17's, and up to 18.10. But I am pleased with my decision making regarding this stock. Since you brought it up.
Can't post a link, but I can tell you via TD Ameritrade that the report was pretty positive, especially regarding the ability to meet upcoming debt obligations, but the price target only $1.50.
Great information.. Thanks..Current market aside, I still think this is a great investment. It's great to own a (small) piece of a growing enterprise. Making real stuff, too!
I think you highlighted one of the headwinds here. Time to market for the collaborations is likely to be long. On the other hand, good news could pop up when unexpected.
Janssen reports NEJM publishing positive trial results for it's new myeloma drug. On which it is partnering with HALO incorporating the ENHAZE delivery system . May be a boost for the shares.
My take. People got a little skittish by a couple of things they observed in the earnings and the call. Maybe the things I noted. Maybe something else. Who knows. I was one of those people. Don't beat me up for it. That was the only high volume selling day. After that it was typical volume but the market has been extreme. It became source of funds. A great chance to buy in again. Seems like the dust hast has settled for HALO. I think the story is intact. She said blockbuster, and there's a good chance she's right, IMO. But if it was cut and dried, the stock would be $50 already. Skepticism is a necessity.
OK, let's talk about the science. The fundamentals that you think you are so well versed in. P
Herceptin SQ has 30% market share. Why not 70-80%? Intuitively this an obviously superior delivery system, but it still has a minority of the market compared to IV, which is pretty unpleasant. Are there equivalence concerns, cost, availability, reimbursement, side effects. Do you know, oh wise one? PEG demonstrated a doubling of PFS, yet the FDA still wants a full phase 3 trial with the additional burden of validated HA metrics, pushing the drug out 1-2 years. Why is that? Seems like a breakthrough to me. What don't we know? What you, and I, know about the science is what the company releases, analysts opine and some knuckleheads on this board say. There's a lot we don't know. So, tell me about the science. I kept a cool head, objectivity, and didn't get sucked into the hysteria, that's my secret.
Bingo. Was in at 7, watched go to 18, and all the way back to 7. Could not do it again. It went from 20 to 25 on the Abbivie deal. It just seemed frothy. Obviously the company is in a vastly improved situation, though. That's why I'm putting my toe back in. If it breaks 15, which I doubt, I'm going to be nervous. I was a little surprised to see only 30% uptake on Herceptin subq. I'll say that. Any thoughts on that?
I know. Some of hate it that I made a boatload of money, while you guys are getting hammered. It was the relentless cheerleading on this board that was one of my key sell signals. Still love the company, but you know what they say about bulls, bears and pigs.
Sold at 24.75. A once in a lifetime windfall. In again and steadily adding to my position under 18. Much fewer shares than I previously held, though. Market risk has obviously increased tremendously. Great company, but to me the cc indicated a longer wait for pivotal results than perhaps many investors had hoped for. Basic story is intact, though, IMO.
SPNS finally succumbing to some selling pressure after remarkable relative strength. It may keep going down, but looks to me like a good opportunity to boost my position another 5-10%.